Ono Pharma Announces an Exclusive License Agreement with Biohaven to Develop and Commercialize IgG Degraders in Japan, South Korea, Taiwan, and ASEAN
Filed with TSE · · 2 pages · English
Summary by 6ix
The agreement includes an upfront payment and milestone payments, along with royalties on net sales, with ONO responsible for clinical development and commercialization. This collaboration aims to enhance ONO's pipeline in immunology and inflammation, targeting the underlying causes of autoimmune diseases.
Written by 6ix from the company’s filing. How 6ix writes summaries
Company: Ono Pharmaceutical Co., Ltd. Representative: Toichi Takino Representative Director, President and COO (Securities Code: 4528 Prime market, TSE) Contact: Ryuta Imura Vice President, Corporate Communications (Phone: +81-6-6263-5670) Ono Pharma Announces an Exclusive License Agreement with Biohaven to Develop and Commercialize IgG Degraders in Japan, South Korea, Taiwan, and ASEAN Countries
ONO Pharmaceutical Co., Ltd. on 6ix
Story so far
- ONO Pharmaceutical: Received Manufacturing and Marketing Approval in Japan for XCOPRI® Tablets for the Treatment of Patients with Partial-onset Seizures, With or Without Secondary Generalized Seizures
- ONO Pharmaceutical: Pharma Submits a Supplemental Application in Japan to Expand the Use of VELEXBRU® Tablets for the Treatment of Central Nervous System Involvement of Malignant Lymphoma in Patients with Inadequate Response to Existing Therapies or in Whom Such Therapies Are Not Appropriate
- Oncolys BioPharma: Announces Full Marketing Approval in Japan for Telomelysin for the Treatment of Esophageal Cancer
Earlier from ONO Pharmaceutical
- Ajinomoto Bio-Pharma Services Unveils Refreshed Global Brand, Showcasing its Strength in Specialization
- ONO Pharmaceutical: Received Manufacturing and Marketing Approval in Japan for XCOPRI® Tablets for the Treatment of Patients with Partial-onset Seizures, With or Without Secondary Generalized Seizures
- Kaneka Ubiquinol™ memenangi nutraingredients Asia Ingredient of the Year: healthspan Award 2026
- OPDIVO® Intravenous Infusion Approved in Taiwan for the Treatment of Resectable Non-Small Cell Lung Cancer with Neoadjuvant OPDIVO in Combination with Chemotherapy Followed by Surgery and Adjuvant Single-Agent OPDIVO
- ONO Pharmaceutical: Continues to be Selected for ESG Investment Indexes Adopted by GPIF
Later from ONO Pharmaceutical
All ONO Pharmaceutical news releasesFollow ONO Pharmaceutical into a list and get an email when it puts out news.
Follow ONO Pharmaceutical